Search results - Portal of Medical Data Models (MDM-Portal)

Itemgroups: MSKCC 00-138; CALGB-90104; ECOG, Form Administration, Vital Status, Disease Follow-Up Status, Notice of Progression, Notice of New Primary, Notice of Long Term Toxicity, Comments, CCRR MODULE

NCI Cooperative Group Follow-Up Form (CALGB-90104) Combination Chemotherapy in Treating Patients With Bladder Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=A9C23658-5AE0-303F-E034-0003BA12F5E7

Follow-Up Form Bladder Cancer (NCT00942331)

- 1/8/15 - 1 form, 8 itemgroups, 44 items, 1 language

Itemgroups: Header, Vital Status, Treatment Status, Disease Assessment, Measurable Disease Response, Notice of New Primary, Long-Term Toxicity, Non-Protocol Therapy

CALGB 90601: Follow-Up Form Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer NCT00942331 Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=6591C082-D8C1-EC1C-E040-BB89AD43479B

Follow-Up - Phase II Lung Cancer - Advanced Disease Follow-Up Form - 2399268v1.0 - Phase II Lung Cancer - Advanced Disease Follow-Up Form

- 9/27/21 - 1 form, 9 itemgroups, 36 items, 1 language

Itemgroups: CRF Header, Form Administration, Lung: Vital Status, Lung: Disease Follow-Up Status, Lung: Notice of Progression/Site, Lung: Subsequent Non-Protocol Therapy, Lung: Notice of New Primary, Lung: Long-Term Toxicity, Comments

Phase II Consortium Phase II Lung Cancer - Advanced Disease Follow-Up Form Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=FF8E0C9E-44F2-3242-E034-0003BA3F9857

Follow-Up - Phase II Lung Cancer - Localized Disease Follow-Up Form - 2402852v1.0 - Phase II Lung Cancer - Localized Disease Follow-Up Form

- 9/27/21 - 1 form, 9 itemgroups, 38 items, 1 language

Itemgroups: CRF Header, Form Administration, Lung: Vital Status, Lung: Disease Follow-Up Status, Lung: Notice of Progression/Site, Lung: Subsequent Non-Protocol Therapy, Lung: Notice of New Primary, Lung: Long-Term Toxicity, Comments

Phase II Consortium Phase II Lung Cancer - Localized Disease Follow-Up Form Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=00212490-27A3-4F0A-E044-0003BA3F9857

Lung Cancer NCT01041781 Response - CALGB: 30801 Follow-Up and Response Form - 2891478v1.0 - CALGB: 30801 Follow-Up and Response Form

- 9/20/21 - 1 form, 6 itemgroups, 33 items, 1 language

Itemgroups: Header Module, Header, Vital Status, Response Data, Non-Protocol Treatment, New Primary Data

CALGB: 30801 Follow-Up and Response Form Gemcitabine Hydrochloride or Pemetrexed Disodium and Carboplatin With or Without Celecoxib in Treating Patients With Advanced Non-Small Cell Lung Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=6AF26CA3-DEA5-EEE0-E040-BB89AD436D54

E1505 Disease and Vital Status Form NCT00324805

- 9/20/21 - 1 form, 12 itemgroups, 45 items, 1 language

Itemgroups: Header, Patient demographics, Data amendment, ON TREATMENT, VITAL STATUS, Section II - Reporting Period, Section III - Notice of New Primary, Disease Follow-Up Status, Biopsy, Section VI - Non-Protocol Therapy Prior To Recurrence, Section VII - Treatment for First Recurrence, Footer Module

E1505 Disease and Vital Status Form NCT00324805 Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-Small Lung Cancer That Was Removed By Surgery Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=07D0C4EF-5573-55B4-E044-0003BA3F9857

E2805 Follow-up Disease Evaluation Form NCT00326898

- 9/20/21 - 1 form, 6 itemgroups, 30 items, 1 language

Itemgroups: ECOG clinical trial administrative data, Data amendment, Cycle number, Section I - Clinical Assessment, Section II - Notice of Recurrence, Footer module

E2805 Follow-up Disease Evaluation Form NCT00326898 Sunitinib or Sorafenib in Treating Patients With Kidney Cancer That Was Removed By Surgery Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=054D0EB8-8174-3DEA-E044-0003BA3F9857

Keywords

Table of contents

Selected data models

Follow-Up - Follow-Up Oncology

Radiation Therapy Oncology Group Follow-up Form Phase III Lung Prophylactic Cranial RT 10363 NCT00048997

Pancreatic Cancer NCT00058149 Follow-Up - Hematology/Chemistry Form - 2048132v3.0 - Hematology/Chemistry Form

Bladder Cancer NCT00014534 Follow-Up - CALGB: 90104 New Primary Cancer Form - 2169482v3.0 - CALGB: 90104 New Primary Cancer Form

Bladder Cancer NCT00445601 Follow-Up - S0337 Disease Assessment and Follow Up Form - 2388951v1.0 - S0337 Disease Assessment and Follow Up Form

Bladder Cancer NCT00014534 Follow-Up - NCI Cooperative Group Follow-Up Form (CALGB-90104) - 2056490v3.0 - NCI Cooperative Group Follow-Up Form (CALGB-90104)